- €13.07bn
- €12.06bn
- €3.93bn
Brief: Ipsen: Elafibranor Shows Favorable Safety Profile And Efficacy In PSC
Europe Research Roundup: Airbus, Deutsche Telekom, L'Oreal
Brief: Ipsen Q1 Revenue At EUR 918.8 Mln
Europe Research Roundup: Adidas, AXA, Greencore
Brief: Ipsen Issues EUR 500 Mln Inaugural Rated Public Bond
Ipsen falls after 'lower-quality' beat on Q4 sales, 2025 guidance
Brief: Ipsen FY 2024 Total Sales Growth Of 9.9% At Cer, 8.7% Reported
Brief: Ipsen FY Adjusted EPS EUR 10.27 Vs. IBES Estimate EUR 9.5
Crinetics gains after TD Cowen starts with 'buy' on optimism for lead drugs
Former exec at drugmaker Ipsen sentenced to prison for insider trading (updated)
Former exec at drugmaker Ipsen sentenced to prison for insider trading
Europe Research Roundup: Aena, Burberry, LVMH
Barclays cautious on European pharma in H1, sees re-rating chance in H2
RBC names specialty pharma and biotech launches to watch in 2025
Top of the Street: European reinsurers, Schindler, Moncler, E.ON, Ipsen
BofA cuts Ipsen citing valuation, shares slip
Brief: Ipsen, Biomunex Announce Exclusive Global Licensing Agreement For BMX-502
Brief: Ipsen Ups FY Guidance, Posts Q3 Revenue Of EUR 836.6 Mln
US FDA declines to approve Camurus' rare hormone disorder drug